E-mail| Contact Us| Volunteer| Make A Gift| En Español| Employees


Learn More

Ann B. Barshinger Cancer Institute

Lung Cancer


Check your lungs

Lung > Immunotherapy

Immunotherapy for Lung Cancer

Immunotherapy is an exciting breakthrough in lung cancer treatment, offering new options and hope for patients who did not adequately respond to chemotherapy.

Immunotherapy taps into the unique powers of the immune system to fight cancer. In 2015 the FDA approved two immunotherapy drugs--nivolumab (Opdivo®) and pembrolizumab (Keytruda®)--for the treatment of lung cancer. Nivolumab was approved for the treatment of squamous and non-squamous NSCLC. Pembrolizumab was approved for the treatment of PD-L1-positive NSCLC.

Immunotherapy has been shown to improve survival in patients with lung cancer compared to second line chemotherapy. These advancements would not have been possible without clinical trials.

Find A Doctor
Advanced Search
Call 1-888-LGH-INFO

Learn More


Contact Us:

1-888-LGH-INFO (544-4636) Have a question?
Follow us online.